Cryoport, Inc. logo

Cryoport, Inc.

CYRX

NASDAQIndustrialsIntegrated Freight & Logistics

Latest quote

$17.11

+$0.42 · +2.51%

Aug 21, 3:55 PM ET

CYRX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

46

Fair Value

Momentum

69

Gaining

Sentiment

70

Bullish

Risk resilience

57

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Central to their offerings is Cryoportal, a proprietary cloud-based platform designed to streamline the entire logistics process. This robust system facilitates order processing, generates necessary documentation (including customs paperwork), coordinates courier services, offers real-time shipment tracking and monitoring, aids in issue resolution, and ensures adherence to regulatory compliance standards. To guarantee the integrity of sensitive materials during transit, Cryoport provides CryoPort Express Shippers, engineered to maintain the stability of biological commodities throughout their journey. Furthermore, their SmartPak Condition Monitoring System collects vital environmental data, which is then utilized to produce informative dashboards and essential validation reports for each shipment. Their product range also includes specialized containment solutions such as vacuum insulated aluminum dewars and advanced cryogenic freezer systems. Beyond transportation, the company offers extensive biological specimen management services. These encompass cryopreservation storage and ongoing maintenance, meticulous archiving, continuous monitoring, precise tracking, and efficient receipt and delivery of samples. They also manage the transport of frozen biological specimens to and from client facilities and oversee the inbound and outbound flow of these critical materials. Additionally, Cryoport extends its expertise through comprehensive logistics support and management services, alongside short-term consulting in both logistics and engineering. The company primarily caters to the biopharmaceutical, animal health, and human reproductive medicine industries. Founded in 1999, Cryoport's headquarters are situated in Brentwood, Tennessee.

Industry
Integrated Freight & Logistics
Sector
Industrials
Headquarters
US
CEO
Jerrell W. Shelton
Listed since
Aug 22, 2005
Employees
688

Market position

Volume
1.03M
1.39× average
Average volume
739.23K
Average daily volume
Market cap
863.39M USD
Beta
1.89
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-20.89×
P/B (TTM)
1.76×
P/S (TTM)
4.63×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
47.08%
Operating margin
-21.25%
Net margin
-19.45%

Financial health

Debt / equity
0.47×
Altman Z-score
1.14
Piotroski F-score
3 of 9

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-25.60%
11 comparable reports
Latest EPS result
-0.2
Estimate -0.19 · Miss by 3.45%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.15-0.26-0.36-0.46Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual -0.42, estimate -0.33, surprise -27.27%, Miss. Q2 2025, reported May 7, 2025: actual -0.22, estimate -0.23, surprise +4.35%, Beat. Q3 2025, reported Aug 5, 2025: actual -0.29, estimate -0.2, surprise -45.00%, Miss. Q4 2025, reported Nov 4, 2025: actual -0.18, estimate -0.23, surprise +21.74%, Beat. Q1 2026, reported Mar 3, 2026: actual -0.21, estimate -0.19, surprise -10.53%, Miss. Q2 2026, reported May 4, 2026: actual -0.23, estimate -0.2, surprise -15.00%, Miss. Q3 2026, reported Aug 6, 2026: actual -0.2, estimate -0.193, surprise -3.45%, Miss. Q4 2026, reported Nov 3, 2026: actual —, estimate -0.19, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates61.91M53.88M45.85M37.82MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual 59.53M USD, estimate 58.5M USD, surprise +1.76%, Beat. Q2 2025, reported May 7, 2025: actual 41.04M USD, estimate 40.21M USD, surprise +2.07%, Beat. Q3 2025, reported Aug 5, 2025: actual 45.45M USD, estimate 41.66M USD, surprise +9.10%, Beat. Q4 2025, reported Nov 4, 2025: actual 44.23M USD, estimate 41.2M USD, surprise +7.36%, Beat. Q1 2026, reported Mar 3, 2026: actual 45.45M USD, estimate 42.85M USD, surprise +6.06%, Beat. Q2 2026, reported May 4, 2026: actual 47.8M USD, estimate 44.86M USD, surprise +6.54%, Beat. Q3 2026, reported Aug 6, 2026: actual 48.97M USD, estimate 48.18M USD, surprise +1.65%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 48.69M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$18.79

9.69% upside
Past 12 months12-month forecastHigh $25.00Average $18.79Low $13.50

Rating distribution

19 ratings
Strong buy00%
Buy1579%
Hold421%
Sell00%
Strong sell00%

Recent analyst actions

12 institutions
Craig-HallummaintainBuy
Leerink PartnersupgradeMarket PerformOutperform
Morgan StanleymaintainEqual Weight

CYRX peers

ETFs holding CYRX

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research CYRX

research.disclaimer